KOSDAQBiotech & Pharma067290

JW Shinyak

₩2,170▲ 1.17%2026-11-18 close
Market Cap
₩121.6B
Turnover
₩1.9B
Volume
860K
Shares out.
56M
PER
12.2×
PBR
3.1×
EPS
₩192
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

JW Shinyak: Clinic Profits Funding an Early Cell Therapy Pipeline

JW Shinyak kept operating margins at 9–11% in 2024–2025 on dermatology and hair-loss clinic products, but revenue fell in both years and its CAR-NK cell therapy pipeline remains at an early stage.

  1. 1

    Revenue peaked at KRW 104.2 billion in 2023 and then fell to KRW 93 billion in 2024 and KRW 81 billion in 2025, two straight years of decline.

  2. 2

    Operating profit was highest in 2024 at KRW 9.95 billion and fell 25.1% to KRW 7.46 billion in 2025.

  3. 3

    Net profit attributable to controlling shareholders of KRW 15.7 billion in 2025 exceeded operating profit of KRW 7.46 billion, suggesting non-operating items contributed.

  4. 4

    Q3 2026 revenue rose 3.3% year on year to KRW 21.3 billion, while operating profit fell 3.2% year on year to KRW 2.61 billion.

  5. 5

    On the pipeline side, securing preclinical CAR-NK cell therapy results and preparing clinical trials is the stated 2026 plan.

02

Business structure

JW Shinyak runs a business centered on prescription clinic products in dermatology and hair loss. Coverage reports that the company is seeing solid growth in domestic and overseas clinic markets.

Its core lines include the topical agent Esroban and the male-pattern hair-loss drug Monad, which coverage describes as market-leading product families producing solid sales.

The hair-loss range covers seven treatments matched to cause, and the company holds an exclusive distribution agreement with Galderma to widen its position in skin and hair care. The business has been broadening from dermatology and urology toward internal-medicine chronic disease markets.

Its product line is being reorganized around Bestidin for peptic ulcers and Rivaro for hyperlipidemia. Its R&D centers on CAR-NK cell therapy, and the company signed a co-research deal with U.S. biotech KURE.AI, investing about USD 0.8 million, to use an AI platform to identify tumor-specific antigens in solid cancers.

The work draws on the in-house R&D team and a research subsidiary, C&C Shinyak Research Institute. The company completed the liquidation of JW Creagene, a former subsidiary handling drug discovery, in 2025, which is read as a move to concentrate R&D resources on core next-generation technologies.

Clinic products remain the revenue core, while the pipeline has not yet reached the stage of contributing revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩20.6B₩2.7B13.1%
2025Q4₩21.1B₩1.4B6.7%
2026Q1₩21.4B₩2.9B13.5%
2026Q2₩21.5B₩3.6B16.6%
2026Q3₩21.3B₩2.6B12.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩102.7B₩4.3B₩1.4B4.2%2.5%69.0%
2023₩104.2B₩5.6B-₩37.4B5.4%−222.8%299.0%
2024₩93B₩10B₩5.1B10.7%18.9%137.2%
2025₩81B₩7.5B₩15.7B9.2%38.4%43.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue was KRW 102.7 billion in 2022 and KRW 104.2 billion in 2023 (up 1.5% year on year), then fell to KRW 93 billion in 2024 (down 10.8%) and KRW 81 billion in 2025 (down 12.9%).

Revenue declined in 2024 and 2025, two consecutive years of decline, with 2023 the largest year and 2025 the smallest across 2022–2025. Operating profit rose from KRW 4.29 billion in 2022 to KRW 5.63 billion in 2023 (up 31.3%) and KRW 9.95 billion in 2024 (up 76.8%).

Revenue fell 10.8% in 2024 while operating profit rose 76.8%, lifting the operating margin to 10.7%. In 2025 operating profit was KRW 7.46 billion (down 25.1%) and the margin 9.2%.

Net profit attributable to controlling shareholders was KRW 1.4 billion in 2022, a net loss of KRW 37.4 billion in 2023 (a swing into loss), KRW 5.08 billion in 2024 (a swing back to profit), and KRW 15.7 billion in 2025 (up 208.1%).

In 2023 operating profit was positive but the net loss reached KRW 37.4 billion, so non-operating items and one-off costs should be examined alongside operating results.

In 2025 net profit attributable to controlling shareholders exceeded operating profit, which suggests a large part of earnings came from non-operating sources. The debt-to-equity ratio moved from 69.0% in 2022 to 299.0% in 2023, 137.2% in 2024, and 43.0% in 2025.

At the end of 2025, total equity was KRW 40.7 billion, all attributable to controlling shareholders, and total liabilities were KRW 17.5 billion. Operating cash flow was KRW 7.13 billion in 2022, KRW 2.56 billion in 2023, KRW 8.44 billion in 2024, and KRW 6.03 billion in 2025.

On a quarterly basis, revenue was KRW 20.6 billion in Q3 2025, KRW 21.1 billion in Q4 2025, KRW 21.4 billion in Q1 2026, KRW 21.5 billion in Q2 2026, and KRW 21.3 billion in Q3 2026, staying in the low-KRW 20 billion range.

Operating profit was KRW 2.7 billion in Q3 2025, KRW 1.42 billion in Q4 2025 (down 47.2% from the prior quarter), KRW 2.88 billion in Q1 2026, KRW 3.58 billion in Q2 2026 (up 24.3%), and KRW 2.61 billion in Q3 2026, with Q2 2026 the highest in the period.

Net profit attributable to controlling shareholders over the most recent four quarters totaled KRW 10.8 billion.

05

Industry analysis

The domestic dermatology and hair-loss market uses cause-specific prescription drugs alongside topical agents, so the breadth of the product line shapes prescribing options.

JW Shinyak, with seven hair-loss treatments and the topical agent Esroban, has been described by coverage as further consolidating its dominance in the skin and hair-loss market.

Shifting the business focus from dermatology and urology toward internal-medicine chronic disease markets can be read as an effort to diversify its end-customer base. In this market a larger product range helps secure prescribing channels, but price competition with products sharing the same ingredients is unavoidable.

In drug development, global licensing markets increasingly favor first-in-class candidates with differentiated mechanisms over simple improved generics. CAR-NK cell therapy is at an early development stage targeting solid tumors, so it depends more on individual data than on sector conditions.

Compared with peers, JW Shinyak relies more heavily on cash generation from clinic products, while listed companies focused on new drugs are typically assessed on pipeline stage and licensing track record.

Across the domestic pharmaceutical sector, research spending is rising, and smaller drugmakers are also competing to secure drug candidates. The company's position in the industry is best judged along two axes: the scale of its hair-loss franchise and the clinical progress of its CAR-NK candidate.

06

Outlook

The company's next formal checkpoint is its 2026 annual report, which will finalize full-year figures including Q4 2026. Revenue was KRW 21.4 billion in Q1 2026, KRW 21.5 billion in Q2, and KRW 21.3 billion in Q3, staying in the mid-KRW 20 billion range without a clear upward trend.

Operating profit was KRW 2.88 billion in Q1 2026, KRW 3.58 billion in Q2, and KRW 2.61 billion in Q3, so quarter-to-quarter variation is wide and whether earnings hold at a steady level is the key point to monitor.

Q3 2026 revenue rising 3.3% year on year could be read as an early sign that the clinic business is moving out of its two-year decline. On expansion, the shift toward internal-medicine chronic disease markets needs to show up as a source of revenue growth.

On the pipeline, securing preclinical results for CAR-NK cell therapy this year alongside concrete roadmap steps for clinical trial preparation is the stated 2026 goal.

The co-research with KURE.AI aims to identify tumor-specific antigens in solid cancers, so how the antigen candidates are narrowed is the next milestone to watch.

Whether the candidate enters clinical development will be confirmed through disclosures and announcements, and until then the pipeline remains an R&D cost with no revenue contribution. The 2027 Q1 quarterly report will show whether quarterly revenue and operating profit remain consistent after Q4 2026.

07

Valuation

PER
12.2×
PBR
3.1×
ROE
26.3%
EPS
₩192
BPS
₩765
Dividend per share
₩0

The market value sits well above total equity of KRW 40.7 billion at the end of 2025, placing the stock in a range with a large premium over book value. The price-to-book ratio is well above 1x, which suggests the market is pricing earnings power rather than asset value.

Earnings-based multiples differ depending on whether they use 2025 net profit attributable to controlling shareholders of KRW 15.7 billion or the most recent four quarters totaling KRW 10.8 billion, reflecting an earnings base that is still recovering from the 2023 net loss.

The move from a loss in 2023 to a profit in 2024, followed by a larger profit in 2025, is confirmed by disclosed results. The dividend yield is low, so comparisons based on shareholder payouts are limited.

The market value is still small, so direct multiple comparisons with large listed biotech companies such as Celltrion or Samsung Biologics are difficult. Even within the sector, earnings capacity and pipeline stage differ, so the interpretation depends on which peers are chosen.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Profitability recovery

The operating margin rose from 4.2% in 2022 to 10.7% in 2024 and held at 9.2% in 2025. Net profit attributable to controlling shareholders swung to KRW 5.08 billion in 2024 and reached KRW 15.7 billion in 2025, up 208.1%. The debt-to-equity ratio fell to 43.0% at the end of 2025 from 299.0% in 2023.

Cash generation from the hair-loss clinic lineup

The hair-loss range includes seven cause-specific treatments. An exclusive distribution agreement with Galderma secures its distribution position in skin and hair care. Market-leading product families including Esroban and Monad are described as a stable source of cash.

Room for pipeline expansion

The CAR-NK cell therapy program targets securing preclinical results and preparing clinical trials in 2026. The co-research with KURE.AI uses an AI-based approach to identify tumor-specific antigens in solid cancers.

Entering the clinic and generating data would open the possibility of out-licensing, which is a medium-term factor.

09

Bear factors

Two consecutive years of revenue decline

Revenue fell from KRW 104.2 billion in 2023 to KRW 93 billion in 2024 and KRW 81 billion in 2025, two straight years of decline. Q3 2026 revenue of KRW 21.3 billion was down 1.3% from the prior quarter. It rose 3.3% year on year, but quarterly revenue has been flat in the mid-KRW 20 billion range.

Volatility in quarterly operating profit

Operating profit fell 25.1% to KRW 7.46 billion in 2025. Q4 2025 operating profit dropped 47.2% from the prior quarter to KRW 1.42 billion before recovering to KRW 3.58 billion in Q2 2026. Q3 2026 operating profit of KRW 2.61 billion was down 3.2% year on year, so the quarterly trend is uneven.

Earnings quality and swings in net profit

In 2023 operating profit was KRW 5.63 billion, yet net profit attributable to controlling shareholders swung to a loss of KRW 37.4 billion. In 2025 that net profit of KRW 15.7 billion exceeded operating profit of KRW 7.46 billion, indicating a sizable non-operating contribution. If net profit relies on factors outside operations, the durability of earnings needs further confirmation.

10

Risk factors

Product concentration and distribution dependence

Clinic products are concentrated in dermatology, hair loss, and urology, and overseas distribution of the hair-loss range depends on the exclusive Galderma agreement. Changes to contract terms or prescribing conditions could affect revenue directly. With revenue declining in 2024 and 2025, this concentration translates into earnings volatility.

Pipeline progress and R&D cost burden

The CAR-NK cell therapy program is still at the preclinical results and clinical preparation stage, so clinical failure or delays remain possible. R&D spending accumulates against operating profit. Given operating profit of KRW 7.46 billion in 2025, the burden of research investment needs to be assessed alongside it.

Share price volatility and trading restrictions

The stock was designated a short-term overheating warning stock on June 24, 2026, and on July 8, 2026 it was removed from that designation and placed on a caution list for one day. Under the warning designation, purchases require a 100% margin deposit and margin lending is not available. Its history of sharp price moves remains a trading risk.

11

What to watch next

  1. End of December 2026

    Progress on securing preclinical results and the clinical trial preparation roadmap for CAR-NK cell therapy, the stated 2026 goal.

  2. End of March 2027

    Filing of the 2026 annual report, which will finalize full-year revenue against KRW 81 billion in 2025, the annual operating margin, and Q4 2026 results.

  3. Before May 15, 2027

    The Q1 2027 quarterly report, showing whether quarterly revenue holds in the mid-KRW 20 billion range and how stable operating profit is quarter to quarter.

  4. During 2027 (date not set)

    Results of the KURE.AI antigen discovery work and whether a clinical trial plan for the CAR-NK candidate is submitted. Entry into clinical development would mark tangible pipeline progress.

12

Overall view

JW Shinyak is a drugmaker whose profitability has recovered on dermatology and hair-loss clinic products, with operating margins of 10.7% in 2024 and 9.2% in 2025.

Revenue, however, peaked at KRW 104.2 billion in 2023 and then declined in 2024 and 2025, and quarterly revenue has stayed between KRW 21.3 billion and KRW 21.5 billion in 2026. Earnings also weakened, with 2025 operating profit down 25.1% and Q3 2026 operating profit down 3.2% year on year.

Net profit attributable to controlling shareholders of KRW 15.7 billion in 2025 exceeded operating profit, so it is worth checking how much of the improvement came from non-operating items. The 2023 net loss of KRW 37.4 billion and the 299.0% debt-to-equity ratio remain records of a year with large financial swings.

Total equity at the end of 2025 was KRW 40.7 billion, and the debt-to-equity ratio had fallen to 43.0%. The pipeline is at an earlier stage, with CAR-NK cell therapy still securing preclinical results and preparing for the clinic, so it does not yet contribute to earnings.

The next checkpoints are the 2026 annual report, due by the end of March 2027, and the Q1 2027 quarterly report, with the CAR-NK preclinical results a 2026 target.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. jw-shinyak.co.kr
  2. topstarnews.net
  3. topstarnews.net
  4. m.news.nate.com
  5. m.news.nate.com
  6. finance.eduinfom.com
  7. joongangenews.com
  8. newspim.com
  9. kmpnews.co.kr
  10. m.news.nate.com
  11. comp.fnguide.com
  12. littlebproject.com
  13. jw-lifescience.co.kr
  14. dailyinvest.kr
  15. judal.co.kr
  16. medicopharma.co.kr
  17. youtube.com
  18. youtube.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis